Clinical Trial Update: MSC and Cyclophosphamide for Acute Graft-Versus-Host Disease (aGVHD) Prophylaxis [Phase 2, Phase 3]

View source ↗

Summary

Phase 2/3 clinical trial evaluating mesenchymal stromal cells with cyclophosphamide for prophylaxis of acute graft-versus-host disease in patients with leukemia…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leukemia
• Multiple Myeloma

Drugs mentioned

• CYCLOPHOSPHAMIDE (Cyclophosphamide)
• Mesenchymal stromal cells

Snippet

Sponsor: National Research Center for Hematology, Russia | Conditions: Leukemia, Multiple Myeloma | Phase 2, Phase 3 | Status: UNKNOWN